{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:23:34Z","timestamp":1776803014895,"version":"3.51.2"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-024-02608-3","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:57:05Z","timestamp":1734627425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection"],"prefix":"10.1186","volume":"21","author":[{"given":"Omer Qutaiba B.","family":"Allela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Ghazanfari Hashemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyede Mozhgan","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhwan Abdul","family":"Kareem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayder Naji","family":"Sameer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohaned","family":"Adil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaylan","family":"Kalavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2608_CR1","doi-asserted-by":"publisher","first-page":"100459","DOI":"10.1016\/j.ijregi.2024.100459","volume":"13","author":"N Haider","year":"2024","unstructured":"Haider N, et al. Global landmark: 2023 marks the worst year for dengue cases with millions infected and thousands of deaths reported. IJID Reg. 2024;13:100459.","journal-title":"IJID Reg"},{"issue":"1","key":"2608_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11262-022-01950-4","volume":"59","author":"SK Roy","year":"2023","unstructured":"Roy SK, Goswami BK, Bhattacharjee S. Genetic characterization of dengue virus from patients presenting multi-serotypic infections in the Northern West Bengal. India Virus Genes. 2023;59(1):45\u201354.","journal-title":"India Virus Genes"},{"issue":"2","key":"2608_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.virol.2010.06.039","volume":"405","author":"H Dong","year":"2010","unstructured":"Dong H, et al. Biochemical and genetic characterization of dengue virus methyltransferase. Virology. 2010;405(2):568\u201378.","journal-title":"Virology"},{"issue":"9","key":"2608_CR4","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1128\/AAC.00561-10","volume":"54","author":"M Qing","year":"2010","unstructured":"Qing M, et al. Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob Agents Chemother. 2010;54(9):3686\u201395.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2608_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/microorganisms11051267","volume":"11","author":"J Phadungsombat","year":"2023","unstructured":"Phadungsombat J, et al. Molecular characterization of dengue virus strains from the 2019\u20132020 Epidemic in Hanoi, Vietnam. Microorganisms. 2023;11(5):1267.","journal-title":"Microorganisms"},{"issue":"7","key":"2608_CR6","doi-asserted-by":"publisher","first-page":"e29775","DOI":"10.1002\/jmv.29775","volume":"96","author":"X Hu","year":"2024","unstructured":"Hu X, et al. Integrated serum proteomic and N-glycoproteomic characterization of dengue patients. J Med Virol. 2024;96(7):e29775.","journal-title":"J Med Virol"},{"issue":"3","key":"2608_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/tropicalmed9030060","volume":"9","author":"Y Rachmawati","year":"2024","unstructured":"Rachmawati Y, et al. Potential way to develop dengue virus detection in aedes larvae as an alternative for dengue active surveillance: a literature review. Trop Med Infect Dis. 2024;9(3):60.","journal-title":"Trop Med Infect Dis"},{"key":"2608_CR8","doi-asserted-by":"publisher","first-page":"101279","DOI":"10.1016\/j.mam.2024.101279","volume":"97","author":"K Muzammil","year":"2024","unstructured":"Muzammil K, et al. NRF2-mediated regulation of lipid pathways in viral infection. Mol Asp Med. 2024;97:101279.","journal-title":"Mol Asp Med"},{"key":"2608_CR9","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1007\/s12035-023-03798-7","volume":"61","author":"S Yasamineh","year":"2023","unstructured":"Yasamineh S, et al. Potential use of the cholesterol transfer inhibitor U18666A as a potent research tool for the study of cholesterol mechanisms in neurodegenerative disorders. Mol Neurobiol. 2023;61:3503\u201327.","journal-title":"Mol Neurobiol"},{"key":"2608_CR10","doi-asserted-by":"publisher","first-page":"106096","DOI":"10.1016\/j.micpath.2023.106096","volume":"179","author":"M Assefi","year":"2023","unstructured":"Assefi M, et al. Potential use of the cholesterol transfer inhibitor U18666A as an antiviral drug for research on various viral infections. Microb Pathog. 2023;179:106096.","journal-title":"Microb Pathog"},{"issue":"1\u20132","key":"2608_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.virusres.2013.03.005","volume":"174","author":"AC Carro","year":"2013","unstructured":"Carro AC, Damonte EB. Requirement of cholesterol in the viral envelope for dengue virus infection. Virus Res. 2013;174(1\u20132):78\u201387.","journal-title":"Virus Res"},{"issue":"1","key":"2608_CR12","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1038\/s41598-019-42803-9","volume":"9","author":"MO Tree","year":"2019","unstructured":"Tree MO, et al. Dengue virus reduces expression of low-density lipoprotein receptor-related protein 1 to facilitate replication in Aedes aegypti. Sci Rep. 2019;9(1):6352.","journal-title":"Sci Rep"},{"issue":"40","key":"2608_CR13","doi-asserted-by":"publisher","first-page":"17345","DOI":"10.1073\/pnas.1010811107","volume":"107","author":"NS Heaton","year":"2010","unstructured":"Heaton NS, et al. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci. 2010;107(40):17345\u201350.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2608_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13071-022-05336-1","volume":"15","author":"N Chotiwan","year":"2022","unstructured":"Chotiwan N, et al. Expression of fatty acid synthase genes and their role in development and arboviral infection of Aedes aegypti. Parasit Vectors. 2022;15(1):233.","journal-title":"Parasit Vectors"},{"issue":"1","key":"2608_CR15","doi-asserted-by":"publisher","first-page":"8743","DOI":"10.1038\/s41598-021-87707-9","volume":"11","author":"CN Farfan-Morales","year":"2021","unstructured":"Farfan-Morales CN, et al. The antiviral effect of metformin on zika and dengue virus infection. Sci Rep. 2021;11(1):8743.","journal-title":"Sci Rep"},{"issue":"5","key":"2608_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/insects15050366","volume":"15","author":"Mamenun","year":"2024","unstructured":"Mamenun, et al. Spatiotemporal characterization of dengue incidence and its correlation to climate parameters in Indonesia. Insects. 2024;15(5):366.","journal-title":"Insects"},{"issue":"1","key":"2608_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12929-024-01030-9","volume":"31","author":"S Sinha","year":"2024","unstructured":"Sinha S, et al. Dengue virus pathogenesis and host molecular machineries. J Biomed Sci. 2024;31(1):43.","journal-title":"J Biomed Sci"},{"issue":"4","key":"2608_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1128\/CMR.00035-09","volume":"22","author":"BE Martina","year":"2009","unstructured":"Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009;22(4):564\u201381.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2608_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00284-020-02284-w","volume":"78","author":"P Bhatt","year":"2021","unstructured":"Bhatt P, et al. Current understanding of the pathogenesis of dengue virus infection. Curr Microbiol. 2021;78(1):17\u201332.","journal-title":"Curr Microbiol"},{"key":"2608_CR20","doi-asserted-by":"crossref","unstructured":"Murugesan A, Manoharan M. Dengue virus. In: Emerging and reemerging viral pathogens. Elsevier; 2020, pp. 281\u2013359.","DOI":"10.1016\/B978-0-12-819400-3.00016-8"},{"issue":"1","key":"2608_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12985-021-01611-2","volume":"18","author":"T Hu","year":"2021","unstructured":"Hu T, et al. The key amino acids of E protein involved in early flavivirus infection: viral entry. Virol J. 2021;18(1):136.","journal-title":"Virol J"},{"issue":"5","key":"2608_CR22","first-page":"e60961","volume":"16","author":"JP Patel","year":"2024","unstructured":"Patel JP, Saiyed F, Hardaswani D. Dengue fever accompanied by neurological manifestations: challenges and treatment. Cureus. 2024;16(5):e60961.","journal-title":"Cureus"},{"issue":"5","key":"2608_CR23","first-page":"e60961","volume":"16","author":"JP Patel","year":"2024","unstructured":"Patel JP, Saiyed F, Hardaswani D. Dengue fever accompanied by neurological manifestations: challenges and treatment. Cureus. 2024;16(5):e60961.","journal-title":"Cureus"},{"issue":"8","key":"2608_CR24","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/vaccines11081328","volume":"11","author":"S Malik","year":"2023","unstructured":"Malik S, et al. Tracing down the updates on dengue virus\u2014molecular biology, antivirals, and vaccine strategies. Vaccines. 2023;11(8):1328.","journal-title":"Vaccines"},{"issue":"7953","key":"2608_CR25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41586-023-05790-6","volume":"615","author":"O Goethals","year":"2023","unstructured":"Goethals O, et al. Blocking NS3\u2013NS4B interaction inhibits dengue virus in non-human primates. Nature. 2023;615(7953):678\u201386.","journal-title":"Nature"},{"issue":"2","key":"2608_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jleuko\/qiad133","volume":"115","author":"S Rawat","year":"2024","unstructured":"Rawat S, et al. Phenotypic alteration by dengue virus serotype 2 delays neutrophil apoptosis and stimulates the release of prosurvival secretome with immunomodulatory functions. J Leukoc Biol. 2024;115(2):276\u201392.","journal-title":"J Leukoc Biol"},{"key":"2608_CR27","doi-asserted-by":"publisher","first-page":"199030","DOI":"10.1016\/j.virusres.2022.199030","volume":"325","author":"P Phumesin","year":"2023","unstructured":"Phumesin P, et al. Cepharanthine inhibits dengue virus production and cytokine secretion. Virus Res. 2023;325:199030.","journal-title":"Virus Res"},{"issue":"3","key":"2608_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/v15030705","volume":"15","author":"MF Lee","year":"2023","unstructured":"Lee MF, Wu YS, Poh CL. Molecular mechanisms of antiviral agents against dengue virus. Viruses. 2023;15(3):705.","journal-title":"Viruses"},{"key":"2608_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jbior.2018.09.002","volume":"71","author":"CE Bowman","year":"2019","unstructured":"Bowman CE, Wolfgang MJ. Role of the malonyl-CoA synthetase ACSF3 in mitochondrial metabolism. Adv Biol Regul. 2019;71:34\u201340.","journal-title":"Adv Biol Regul"},{"issue":"10","key":"2608_CR30","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.3390\/ijms21103544","volume":"21","author":"M Abu-Farha","year":"2020","unstructured":"Abu-Farha M, et al. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int J Mol Sci. 2020;21(10):3544.","journal-title":"Int J Mol Sci"},{"key":"2608_CR31","doi-asserted-by":"publisher","first-page":"749770","DOI":"10.3389\/fphys.2021.749770","volume":"12","author":"CN Farfan-Morales","year":"2021","unstructured":"Farfan-Morales CN, et al. Anti-flavivirus properties of lipid-lowering drugs. Front Physiol. 2021;12:749770.","journal-title":"Front Physiol"},{"issue":"2","key":"2608_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.virol.2013.04.003","volume":"442","author":"R Soto-Acosta","year":"2013","unstructured":"Soto-Acosta R, et al. The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity. Virology. 2013;442(2):132\u201347.","journal-title":"Virology"},{"key":"2608_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-017-0685-9","volume":"14","author":"N Tongluan","year":"2017","unstructured":"Tongluan N, et al. Involvement of fatty acid synthase in dengue virus infection. Virol J. 2017;14:1\u201318.","journal-title":"Virol J"},{"issue":"5","key":"2608_CR34","doi-asserted-by":"publisher","first-page":"e01664","DOI":"10.1128\/jvi.01664-21","volume":"96","author":"AC Alcal\u00e1","year":"2022","unstructured":"Alcal\u00e1 AC, et al. Dengue virus NS1 uses scavenger receptor B1 as a cell receptor in cultured cells. J Virol. 2022;96(5):e01664-e1721.","journal-title":"J Virol"},{"key":"2608_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01974-20","author":"DR Coelho","year":"2021","unstructured":"Coelho DR, et al. ApoA1 neutralizes proinflammatory effects of dengue virus NS1 protein and modulates viral immune evasion. J Virol. 2021. https:\/\/doi.org\/10.1128\/jvi.01974-20.","journal-title":"J Virol"},{"issue":"8","key":"2608_CR36","doi-asserted-by":"publisher","first-page":"e1011587","DOI":"10.1371\/journal.ppat.1011587","volume":"19","author":"AC Alcal\u00e1","year":"2023","unstructured":"Alcal\u00e1 AC, Ludert JE. The dengue virus NS1 protein; New roles in pathogenesis due to similarities with and affinity for the high-density lipoprotein (HDL)? PLoS Pathog. 2023;19(8):e1011587.","journal-title":"PLoS Pathog"},{"issue":"19","key":"2608_CR37","doi-asserted-by":"publisher","first-page":"10182","DOI":"10.3390\/ijms221910182","volume":"22","author":"GE Kluck","year":"2021","unstructured":"Kluck GE, et al. Good cholesterol gone bad? HDL and COVID-19. Int J Mol Sci. 2021;22(19):10182.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2608_CR38","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s42003-020-01254-z","volume":"3","author":"C Koh","year":"2020","unstructured":"Koh C, et al. Dengue virus dominates lipid metabolism modulations in Wolbachia-coinfected Aedes aegypti. Commun Biol. 2020;3(1):518.","journal-title":"Commun Biol"},{"issue":"2","key":"2608_CR39","doi-asserted-by":"publisher","first-page":"e02495","DOI":"10.1128\/mbio.02495-23","volume":"15","author":"RK Loterio","year":"2024","unstructured":"Loterio RK, et al. Antiviral Wolbachia strains associate with Aedes aegypti endoplasmic reticulum membranes and induce lipid droplet formation to restrict dengue virus replication. MBio. 2024;15(2):e02495-e2523.","journal-title":"MBio"},{"issue":"8","key":"2608_CR40","doi-asserted-by":"publisher","first-page":"e1010763","DOI":"10.1371\/journal.ppat.1010763","volume":"18","author":"M Yousefi","year":"2022","unstructured":"Yousefi M, et al. TMEM41B and VMP1 modulate cellular lipid and energy metabolism for facilitating dengue virus infection. PLoS Pathog. 2022;18(8):e1010763.","journal-title":"PLoS Pathog"},{"issue":"7","key":"2608_CR41","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/microorganisms11071851","volume":"11","author":"L Herrera-Moro Huitron","year":"2023","unstructured":"Herrera-Moro Huitron L, et al. Multifaceted nature of lipid droplets in viral interactions and pathogenesis. Microorganisms. 2023;11(7):1851.","journal-title":"Microorganisms"},{"issue":"10","key":"2608_CR42","doi-asserted-by":"publisher","first-page":"e1000632","DOI":"10.1371\/journal.ppat.1000632","volume":"5","author":"MM Samsa","year":"2009","unstructured":"Samsa MM, et al. Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog. 2009;5(10):e1000632.","journal-title":"PLoS Pathog"},{"issue":"1","key":"2608_CR43","doi-asserted-by":"publisher","first-page":"19928","DOI":"10.1038\/srep19928","volume":"6","author":"ABF Barletta","year":"2016","unstructured":"Barletta ABF, et al. Emerging role of lipid droplets in Aedes aegypti immune response against bacteria and Dengue virus. Sci Rep. 2016;6(1):19928.","journal-title":"Sci Rep"},{"issue":"4","key":"2608_CR44","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/JLB.4MA0620-658R","volume":"108","author":"G Barbosa-Lima","year":"2020","unstructured":"Barbosa-Lima G, et al. Dengue virus-activated platelets modulate monocyte immunometabolic response through lipid droplet biogenesis and cytokine signaling. J Leucoc Biol. 2020;108(4):1293\u2013306.","journal-title":"J Leucoc Biol"},{"issue":"5","key":"2608_CR45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.chom.2010.10.006","volume":"8","author":"NS Heaton","year":"2010","unstructured":"Heaton NS, Randall G. Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe. 2010;8(5):422\u201332.","journal-title":"Cell Host Microbe"},{"issue":"3","key":"2608_CR46","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/JLB.4MR0119-035R","volume":"106","author":"FS Pereira-Dutra","year":"2019","unstructured":"Pereira-Dutra FS, et al. Fat, fight, and beyond: the multiple roles of lipid droplets in infections and inflammation. J Leukoc Biol. 2019;106(3):563\u201380.","journal-title":"J Leukoc Biol"},{"key":"2608_CR47","doi-asserted-by":"publisher","first-page":"651952","DOI":"10.3389\/fmicb.2021.651952","volume":"12","author":"K Wu","year":"2021","unstructured":"Wu K, et al. Molecular events occurring in lipophagy and its regulation in flaviviridae infection. Front Microbiol. 2021;12:651952.","journal-title":"Front Microbiol"},{"issue":"3","key":"2608_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1590\/s0004-2803.230302023-03","volume":"60","author":"GHDPE Souza","year":"2023","unstructured":"Souza GHDPE, et al. High-density lipoprotein cholesterol and systemic arterial hypertension are associated with hepatic necroinflammatory activity in patients with chronic hepatitis C. Arquivos de Gastroenterologia. 2023;60(3):287\u201399.","journal-title":"Arquivos de Gastroenterologia"},{"issue":"9","key":"2608_CR49","doi-asserted-by":"publisher","first-page":"e00635","DOI":"10.1128\/jvi.00635-24","volume":"98","author":"J-F Zhou","year":"2024","unstructured":"Zhou J-F, et al. Two novel compounds inhibit Flavivirus infection in vitro and in vivo by targeting lipid metabolism. J Virol. 2024;98(9):e00635\u2013724.","journal-title":"J Virol"},{"issue":"7","key":"2608_CR50","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3390\/v15071465","volume":"15","author":"JF Osuna-Ramos","year":"2023","unstructured":"Osuna-Ramos JF, et al. Cholesterol-lowering drugs as potential antivirals: a repurposing approach against flavivirus infections. Viruses. 2023;15(7):1465.","journal-title":"Viruses"},{"issue":"1\u20132","key":"2608_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.virol.2009.03.025","volume":"389","author":"C Rothwell","year":"2009","unstructured":"Rothwell C, et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology. 2009;389(1\u20132):8\u201319.","journal-title":"Virology"},{"issue":"1","key":"2608_CR52","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.antiviral.2011.11.014","volume":"93","author":"MK Poh","year":"2012","unstructured":"Poh MK, et al. U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication. Antivir Res. 2012;93(1):191\u20138.","journal-title":"Antivir Res"},{"issue":"13","key":"2608_CR53","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1128\/JVI.00117-08","volume":"82","author":"C-J Lee","year":"2008","unstructured":"Lee C-J, et al. Cholesterol effectively blocks entry of flavivirus. J Virol. 2008;82(13):6470\u201380.","journal-title":"J Virol"},{"issue":"5","key":"2608_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2217\/fvl.15.35","volume":"10","author":"V Castilla","year":"2015","unstructured":"Castilla V, Piccini LE, Damonte EB. Dengue virus entry and trafficking: perspectives as antiviral target for prevention and therapy. Futur Virol. 2015;10(5):625\u201345.","journal-title":"Futur Virol"},{"issue":"2","key":"2608_CR55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1139\/W08-107","volume":"55","author":"T Peng","year":"2009","unstructured":"Peng T, et al. Entry of dengue virus serotype 2 into ECV304 cells depends on clathrin-dependent endocytosis, but not on caveolae-dependent endocytosis. Can J Microbiol. 2009;55(2):139\u201345.","journal-title":"Can J Microbiol"},{"issue":"18","key":"2608_CR56","doi-asserted-by":"publisher","first-page":"9245","DOI":"10.1128\/JVI.00975-08","volume":"82","author":"M Umashankar","year":"2008","unstructured":"Umashankar M, et al. Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J Virol. 2008;82(18):9245\u201353.","journal-title":"J Virol"},{"issue":"8","key":"2608_CR57","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1128\/JVI.79.8.4557-4567.2005","volume":"79","author":"J Reyes-del Valle","year":"2005","unstructured":"Reyes-del Valle J, et al. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol. 2005;79(8):4557\u201367.","journal-title":"J Virol"},{"issue":"10","key":"2608_CR58","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/j.1462-5822.2009.01345.x","volume":"11","author":"EG Acosta","year":"2009","unstructured":"Acosta EG, Castilla V, Damonte EB. Alternative infectious entry pathways for dengue virus serotypes into mammalian cells. Cell Microbiol. 2009;11(10):1533\u201349.","journal-title":"Cell Microbiol"},{"issue":"1","key":"2608_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/imm.12617","volume":"149","author":"P Varshney","year":"2016","unstructured":"Varshney P, Yadav V, Saini N. Lipid rafts in immune signalling: current progress and future perspective. Immunology. 2016;149(1):13\u201324.","journal-title":"Immunology"},{"key":"2608_CR60","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3389\/fimmu.2020.01320","volume":"11","author":"S Kara","year":"2020","unstructured":"Kara S, et al. Impact of plasma membrane domains on IgG Fc receptor function. Front Immunol. 2020;11:1320.","journal-title":"Front Immunol"},{"issue":"2","key":"2608_CR61","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1099\/vir.0.015420-0","volume":"91","author":"H Puerta-Guardo","year":"2010","unstructured":"Puerta-Guardo H, et al. Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains. J Gen Virol. 2010;91(2):394\u2013403.","journal-title":"J Gen Virol"},{"issue":"9","key":"2608_CR62","doi-asserted-by":"publisher","first-page":"e0003904","DOI":"10.1371\/journal.pntd.0003904","volume":"9","author":"HH Biswas","year":"2015","unstructured":"Biswas HH, et al. Lower low-density lipoprotein cholesterol levels are associated with severe dengue outcome. PLoS Negl Trop Dis. 2015;9(9):e0003904.","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"2608_CR63","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/jme\/tjv101","volume":"52","author":"Q Fu","year":"2015","unstructured":"Fu Q, et al. Sterol carrier protein 2, a critical host factor for dengue virus infection, alters the cholesterol distribution in mosquito Aag2 cells. J Med Entomol. 2015;52(5):1124\u201334.","journal-title":"J Med Entomol"},{"issue":"7","key":"2608_CR64","doi-asserted-by":"publisher","first-page":"7674","DOI":"10.48048\/tis.2024.7674","volume":"21","author":"RI Ahmad","year":"2024","unstructured":"Ahmad RI, et al. Apolipoproteins and its association with dengue virus serotype 2 (DENV-2) infectivity in human hepatoma cell line (Huh7). Trends Sci. 2024;21(7):7674\u20137674.","journal-title":"Trends Sci"},{"issue":"6","key":"2608_CR65","doi-asserted-by":"publisher","first-page":"e38202","DOI":"10.1371\/journal.pone.0038202","volume":"7","author":"J Pe\u00f1a","year":"2012","unstructured":"Pe\u00f1a J, Harris E. Early dengue virus protein synthesis induces extensive rearrangement of the endoplasmic reticulum independent of the UPR and SREBP-2 pathway. PLoS ONE. 2012;7(6):e38202.","journal-title":"PLoS ONE"},{"issue":"1","key":"2608_CR66","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12964-023-01376-x","volume":"21","author":"I Ahmad","year":"2023","unstructured":"Ahmad I, et al. An overview of the role of Niemann-pick C1 (NPC1) in viral infections and inhibition of viral infections through NPC1 inhibitor. Cell Commun Signal. 2023;21(1):352.","journal-title":"Cell Commun Signal"},{"issue":"8","key":"2608_CR67","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1021\/acsinfecdis.0c00018","volume":"6","author":"AS Gold","year":"2020","unstructured":"Gold AS, et al. Examining the role of Niemann\u2013Pick C1 protein in the permissiveness of Aedes mosquitoes to filoviruses. ACS Infect Dis. 2020;6(8):2023\u20138.","journal-title":"ACS Infect Dis"},{"issue":"1","key":"2608_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dci.2013.10.002","volume":"43","author":"N Jupatanakul","year":"2014","unstructured":"Jupatanakul N, Sim S, Dimopoulos G. Aedes aegypti ML and Niemann\u2013Pick type C family members are agonists of dengue virus infection. Dev Comp Immunol. 2014;43(1):1\u20139.","journal-title":"Dev Comp Immunol"},{"issue":"1","key":"2608_CR69","first-page":"646303","volume":"2015","author":"J Guevara Jr","year":"2015","unstructured":"Guevara J Jr, et al. Analogs of LDL receptor ligand motifs in dengue envelope and capsid proteins as potential codes for cell entry. J Viruses. 2015;2015(1):646303.","journal-title":"J Viruses"},{"key":"2608_CR70","doi-asserted-by":"crossref","unstructured":"Huerta V, et al. The low-density lipoprotein receptor-related protein-1 is essential for Dengue virus infection. bioRxiv. 2020;2020.06. 10.144089.","DOI":"10.1101\/2020.06.10.144089"},{"key":"2608_CR71","doi-asserted-by":"publisher","first-page":"197672","DOI":"10.1016\/j.virusres.2019.197672","volume":"271","author":"L Sreelatha","year":"2019","unstructured":"Sreelatha L, et al. Serine protease inhibitor AEBSF reduces dengue virus infection via decreased cholesterol synthesis. Virus Res. 2019;271:197672.","journal-title":"Virus Res"},{"issue":"9","key":"2608_CR72","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3390\/ijms18091957","volume":"18","author":"J-M Chen","year":"2017","unstructured":"Chen J-M, et al. Bovine lactoferrin inhibits dengue virus infectivity by interacting with heparan sulfate, low-density lipoprotein receptor, and DC-SIGN. Int J Mol Sci. 2017;18(9):1957.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2608_CR73","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.scib.2020.08.035","volume":"66","author":"K Wang","year":"2021","unstructured":"Wang K, et al. Cyclovirobuxine D inhibits dengue virus replication by impeding the complete autophagy in a cholesterol-dependent manner. Sci Bull. 2021;66(3):284\u201396.","journal-title":"Sci Bull"},{"issue":"18","key":"2608_CR74","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.3390\/molecules26185501","volume":"26","author":"T Ratanakomol","year":"2021","unstructured":"Ratanakomol T, et al. Berberine inhibits dengue virus through dual mechanisms. Molecules. 2021;26(18):5501.","journal-title":"Molecules"},{"key":"2608_CR75","doi-asserted-by":"publisher","first-page":"101054","DOI":"10.1016\/j.plipres.2020.101054","volume":"79","author":"AM Gorabi","year":"2020","unstructured":"Gorabi AM, et al. Antiviral effects of statins. Prog Lipid Res. 2020;79:101054.","journal-title":"Prog Lipid Res"},{"issue":"4","key":"2608_CR76","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/ehjcvp\/pvaa042","volume":"6","author":"V Castiglione","year":"2020","unstructured":"Castiglione V, et al. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):258\u20139.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"2608_CR77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/imm.12902","volume":"154","author":"R Zeiser","year":"2018","unstructured":"Zeiser R. Immune modulatory effects of statins. Immunology. 2018;154(1):69\u201375.","journal-title":"Immunology"},{"issue":"3","key":"2608_CR78","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.antiviral.2013.06.018","volume":"99","author":"DS Fedson","year":"2013","unstructured":"Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013;99(3):417\u201335.","journal-title":"Antiviral Res"},{"issue":"10","key":"2608_CR79","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","volume":"52","author":"B Chauvin","year":"2013","unstructured":"Chauvin B, et al. Drug\u2013drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815\u201331.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2608_CR80","doi-asserted-by":"publisher","first-page":"17147","DOI":"10.1038\/s41598-018-35334-2","volume":"8","author":"PY Chia","year":"2018","unstructured":"Chia PY, et al. Hyperlipidemia, statin use and dengue severity. Sci Rep. 2018;8(1):17147.","journal-title":"Sci Rep"},{"issue":"4","key":"2608_CR81","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/cid\/civ949","volume":"62","author":"J Whitehorn","year":"2016","unstructured":"Whitehorn J, et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2016;62(4):468\u201376.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2608_CR82","doi-asserted-by":"publisher","first-page":"e87412","DOI":"10.1371\/journal.pone.0087412","volume":"9","author":"M Martinez-Gutierrez","year":"2014","unstructured":"Martinez-Gutierrez M, et al. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS ONE. 2014;9(2):e87412.","journal-title":"PLoS ONE"},{"key":"2608_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-13-203","volume":"13","author":"J Whitehorn","year":"2012","unstructured":"Whitehorn J, et al. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. Trials. 2012;13:1\u20136.","journal-title":"Trials"},{"issue":"3","key":"2608_CR84","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3892\/mmr.2016.5519","volume":"14","author":"OL Bryan-Marrugo","year":"2016","unstructured":"Bryan-Marrugo OL, et al. The anti-dengue virus properties of statins may be associated with alterations in the cellular antiviral profile expression. Mol Med Rep. 2016;14(3):2155\u201363.","journal-title":"Mol Med Rep"},{"key":"2608_CR85","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.antiviral.2018.10.024","volume":"160","author":"JF Osuna-Ramos","year":"2018","unstructured":"Osuna-Ramos JF, et al. Ezetimibe inhibits Dengue virus infection in Huh-7 cells by blocking the cholesterol transporter Niemann-Pick C1-like 1 receptor. Antiviral Res. 2018;160:151\u201364.","journal-title":"Antiviral Res"},{"issue":"4","key":"2608_CR86","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000321892","volume":"54","author":"M Mart\u00ednez-Gutierrez","year":"2011","unstructured":"Mart\u00ednez-Gutierrez M, Castellanos JE, Gallego-G\u00f3mez JC. Statins reduce dengue virus production via decreased virion assembly. Intervirology. 2011;54(4):202\u201316.","journal-title":"Intervirology"},{"issue":"12","key":"2608_CR87","doi-asserted-by":"publisher","first-page":"108294","DOI":"10.1016\/j.isci.2023.108294","volume":"26","author":"SN Palacios-R\u00e1palo","year":"2023","unstructured":"Palacios-R\u00e1palo SN, et al. An ivermectin\u2013atorvastatin combination impairs nuclear transport inhibiting dengue infection in vitro and in vivo. Iscience. 2023;26(12):108294.","journal-title":"Iscience"},{"key":"2608_CR88","doi-asserted-by":"publisher","first-page":"109082","DOI":"10.1016\/j.intimp.2022.109082","volume":"112","author":"R Niranjan","year":"2022","unstructured":"Niranjan R, et al. Atorvastatin attenuates NS1 (Non-structural protein-1) of dengue type-2 serotype-induced expressions of matrix metalloproteinases in HL-60 cells, differentiated to neutrophils: implications for the immunopathogenesis of dengue viral disease. Int Immunopharmacol. 2022;112:109082.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2608_CR89","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40265-024-01995-9","volume":"84","author":"WA Schonck","year":"2024","unstructured":"Schonck WA, et al. Long-term efficacy and tolerability of PCSK9 targeted therapy: a review of the literature. Drugs. 2024;84(2):165\u201378.","journal-title":"Drugs"},{"issue":"2","key":"2608_CR90","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/eurheartj\/ehz566","volume":"41","author":"H-D Jang","year":"2020","unstructured":"Jang H-D, et al. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin\/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin\/kexin type-9. Eur Heart J. 2020;41(2):239\u201352.","journal-title":"Eur Heart J"},{"issue":"4","key":"2608_CR91","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283(4):2363\u201372.","journal-title":"J Biol Chem"},{"issue":"5","key":"2608_CR92","doi-asserted-by":"publisher","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"M Canuel","year":"2013","unstructured":"Canuel M, et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE. 2013;8(5):e64145.","journal-title":"PLoS ONE"},{"issue":"11","key":"2608_CR93","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.3390\/ijms22115880","volume":"22","author":"C Barale","year":"2021","unstructured":"Barale C, et al. PCSK9 biology and its role in atherothrombosis. Int J Mol Sci. 2021;22(11):5880.","journal-title":"Int J Mol Sci"},{"key":"2608_CR94","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.jlr.2021.100130","volume":"62","author":"NG Seidah","year":"2021","unstructured":"Seidah NG. The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer. J Lipid Res. 2021;62:100130.","journal-title":"J Lipid Res"},{"issue":"1","key":"2608_CR95","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9(1):13.","journal-title":"Signal Transduct Target Ther"},{"issue":"20","key":"2608_CR96","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.2174\/1568026619666190809094203","volume":"19","author":"B Chen","year":"2019","unstructured":"Chen B, et al. A review of PCSK9 inhibitors and their effects on cardiovascular diseases. Curr Top Med Chem. 2019;19(20):1790\u2013817.","journal-title":"Curr Top Med Chem"},{"issue":"6","key":"2608_CR97","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1194\/jlr.E800008-JLR200","volume":"49","author":"AS Peterson","year":"2008","unstructured":"Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008;49(6):1152\u20136.","journal-title":"J Lipid Res"},{"issue":"12","key":"2608_CR98","first-page":"745","volume":"77","author":"A Scheen","year":"2022","unstructured":"Scheen A, Wallemacq C, Lancellotti P. Inclisiran (Leqvio\u00ae), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy. Rev Med Liege. 2022;77(12):745\u201351.","journal-title":"Rev Med Liege"},{"issue":"1","key":"2608_CR99","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ymthe.2018.10.016","volume":"27","author":"M Khoshnejad","year":"2019","unstructured":"Khoshnejad M, et al. Development of novel DNA-encoded PCSK9 monoclonal antibodies as lipid-lowering therapeutics. Mol Ther. 2019;27(1):188\u201399.","journal-title":"Mol Ther"},{"key":"2608_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2018.01.025","volume":"130","author":"A Baragetti","year":"2018","unstructured":"Baragetti A, et al. Proprotein convertase subtilisin-kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: facts and gaps. Pharmacol Res. 2018;130:1\u201311.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2608_CR101","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2014.08.038","volume":"237","author":"TP Leren","year":"2014","unstructured":"Leren TP. Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis. 2014;237(1):76\u201381.","journal-title":"Atherosclerosis"},{"key":"2608_CR102","doi-asserted-by":"publisher","first-page":"1148486","DOI":"10.3389\/fcvm.2023.1148486","volume":"10","author":"M Ma","year":"2023","unstructured":"Ma M, Hou C, Liu J. Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: focus on immune regulation. Front Cardiovasc Med. 2023;10:1148486.","journal-title":"Front Cardiovasc Med"},{"key":"2608_CR103","doi-asserted-by":"publisher","first-page":"1272055","DOI":"10.3389\/fimmu.2023.1272055","volume":"14","author":"P Noe","year":"2023","unstructured":"Noe P, et al. Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies. Front Immunol. 2023;14:1272055.","journal-title":"Front Immunol"},{"issue":"23","key":"2608_CR104","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.jacc.2014.01.054","volume":"63","author":"D Tousoulis","year":"2014","unstructured":"Tousoulis D, et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol. 2014;63(23):2491\u2013502.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2608_CR105","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1194\/jlr.M003566","volume":"51","author":"B Dong","year":"2010","unstructured":"Dong B, et al. Strong induction of PCSK9 gene expression through HNF1\u03b1 and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010;51(6):1486\u201395.","journal-title":"J Lipid Res"},{"issue":"2","key":"2608_CR106","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","volume":"201","author":"J Cameron","year":"2008","unstructured":"Cameron J, et al. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008;201(2):266\u201373.","journal-title":"Atherosclerosis"},{"issue":"3","key":"2608_CR107","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","volume":"81","author":"EP Navarese","year":"2023","unstructured":"Navarese EP, et al. PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection. J Am Coll Cardiol. 2023;81(3):224\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2608_CR108","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/cvr\/cvz003","volume":"115","author":"NG Seidah","year":"2019","unstructured":"Seidah NG, et al. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Cardiovasc Res. 2019;115(3):510\u20138.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"2608_CR109","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.4049\/jimmunol.167.11.6140","volume":"167","author":"CC Caldwell","year":"2001","unstructured":"Caldwell CC, et al. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol. 2001;167(11):6140\u20139.","journal-title":"J Immunol"},{"issue":"1","key":"2608_CR110","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1099\/jgv.0.000987","volume":"99","author":"Z Li","year":"2018","unstructured":"Li Z, Liu Q. Proprotein convertase subtilisin\/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. J Gen Virol. 2018;99(1):44\u201361.","journal-title":"J Gen Virol"},{"issue":"14","key":"2608_CR111","doi-asserted-by":"publisher","first-page":"e016263","DOI":"10.1161\/JAHA.120.016263","volume":"9","author":"TM Leucker","year":"2020","unstructured":"Leucker TM, et al. Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia. J Am Heart Assoc. 2020;9(14):e016263.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2608_CR112","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hep.22911","volume":"50","author":"P Labont\u00e9","year":"2009","unstructured":"Labont\u00e9 P, et al. PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression. Hepatology. 2009;50(1):17\u201324.","journal-title":"Hepatology"},{"issue":"10","key":"2608_CR113","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1172\/JCI137536","volume":"130","author":"ES Gan","year":"2020","unstructured":"Gan ES, et al. Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes. J Clin Investig. 2020;130(10):5223\u201334.","journal-title":"J Clin Investig"},{"issue":"10","key":"2608_CR114","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1161\/ATVBAHA.119.313247","volume":"39","author":"A Ben Djoudi Ouadda","year":"2019","unstructured":"Ben Djoudi Ouadda A, et al. Ser-phosphorylation of PCSK9 (proprotein convertase subtilisin-kexin 9) by Fam20C (family with sequence similarity 20, member C) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor). Arterioscler Thromb Vasc Biol. 2019;39(10):1996\u20132013.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2608_CR115","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41541-023-00743-6","volume":"8","author":"A Fowler","year":"2023","unstructured":"Fowler A, et al. A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates. npj Vaccines. 2023;8(1):142.","journal-title":"npj Vaccines"},{"key":"2608_CR116","doi-asserted-by":"publisher","first-page":"199018","DOI":"10.1016\/j.virusres.2022.199018","volume":"324","author":"BH Kok","year":"2023","unstructured":"Kok BH, et al. Dengue virus infection\u2014a review of pathogenesis, vaccines, diagnosis and therapy. Virus Res. 2023;324:199018.","journal-title":"Virus Res"},{"issue":"2","key":"2608_CR117","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40506-023-00263-w","volume":"15","author":"M Palanichamy Kala","year":"2023","unstructured":"Palanichamy Kala M, St. John AL, Rathore AP. Dengue: update on clinically relevant therapeutic strategies and vaccines. Curr Treat Options Infect Dis. 2023;15(2):27\u201352.","journal-title":"Curr Treat Options Infect Dis"},{"issue":"2","key":"2608_CR118","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/0976500X231204401","volume":"14","author":"AA Hershan","year":"2023","unstructured":"Hershan AA. Dengue virus: molecular biology and recent developments in control strategies, prevention, management, and therapeutics. J Pharmacol Pharmacother. 2023;14(2):107\u201324.","journal-title":"J Pharmacol Pharmacother"},{"issue":"10","key":"2608_CR119","doi-asserted-by":"publisher","first-page":"e586","DOI":"10.1093\/cid\/ciaa1332","volume":"72","author":"Y Suputtamongkol","year":"2021","unstructured":"Suputtamongkol Y, et al. Ivermectin accelerates circulating nonstructural protein 1 (NS1) clearance in adult dengue patients: a combined phase 2\/3 randomized double-blinded placebo controlled trial. Clin Infect Dis. 2021;72(10):e586\u201393.","journal-title":"Clin Infect Dis"},{"key":"2608_CR120","doi-asserted-by":"crossref","unstructured":"Yadav M, et al. Medicinal plants and herbs in the treatment of dengue virus. In: Promising antiviral herbal and medicinal plants. CRC Press; 2024, pp. 101\u2013120.","DOI":"10.1201\/9781003329169-8"},{"issue":"1","key":"2608_CR121","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.antiviral.2010.11.002","volume":"89","author":"J Chang","year":"2011","unstructured":"Chang J, et al. Combination of \u03b1-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011;89(1):26\u201334.","journal-title":"Antiviral Res"},{"key":"2608_CR122","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2020.07.009","volume":"43","author":"B Troost","year":"2020","unstructured":"Troost B, Smit JM. Recent advances in antiviral drug development towards dengue virus. Curr Opin Virol. 2020;43:9\u201321.","journal-title":"Curr Opin Virol"},{"issue":"2","key":"2608_CR123","doi-asserted-by":"publisher","first-page":"e2413","DOI":"10.1002\/rmv.2413","volume":"33","author":"YJ Gee","year":"2023","unstructured":"Gee YJ, Sea YL, Lal SK. Viral modulation of lipid rafts and their potential as putative antiviral targets. Rev Med Virol. 2023;33(2):e2413.","journal-title":"Rev Med Virol"},{"issue":"1","key":"2608_CR124","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12964-023-01250-w","volume":"21","author":"X Meng","year":"2023","unstructured":"Meng X, et al. The roles of different microRNAs in the regulation of cholesterol in viral hepatitis. Cell Commun Signal. 2023;21(1):231.","journal-title":"Cell Commun Signal"},{"issue":"19","key":"2608_CR125","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.3390\/jcm11195626","volume":"11","author":"BR Wu","year":"2022","unstructured":"Wu BR, et al. Statin therapy and the risk of viral infection: a retrospective population-based cohort study. J Clin Med. 2022;11(19):5626.","journal-title":"J Clin Med"},{"issue":"1","key":"2608_CR126","doi-asserted-by":"publisher","first-page":"11461","DOI":"10.1038\/s41598-019-47956-1","volume":"9","author":"E Espa\u00f1o","year":"2019","unstructured":"Espa\u00f1o E, et al. Lipophilic statins inhibit Zika virus production in Vero cells. Sci Rep. 2019;9(1):11461.","journal-title":"Sci Rep"},{"issue":"4","key":"2608_CR127","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/cid\/civ949","volume":"62","author":"J Whitehorn","year":"2016","unstructured":"Whitehorn J, et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind. Placebo-Control Trial Clin Infect Dis. 2016;62(4):468\u201376.","journal-title":"Placebo-Control Trial Clin Infect Dis"},{"issue":"1","key":"2608_CR128","doi-asserted-by":"publisher","first-page":"22","DOI":"10.31083\/j.rcm2401022","volume":"24","author":"A Chaulin","year":"2023","unstructured":"Chaulin A. Cardiotoxicity as a possible side effect of statins. Rev Cardiovasc Med. 2023;24(1):22.","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"2608_CR129","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/JS9.0000000000000010","volume":"109","author":"S Sekaran","year":"2023","unstructured":"Sekaran S, Sekar SKR. Repurposing cholesterol lowering drugs in the treatment and management of monkeypox. Int J Surg. 2023;109(1):60\u20131.","journal-title":"Int J Surg"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02608-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02608-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02608-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T18:03:44Z","timestamp":1734631424000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02608-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2608"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02608-3","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are consent to the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"324"}}